|
|

Title: Method for preventing sexually transmitted
diseases
United States Patent: 6,239,182
Inventors: Zaneveld; Lourens Jan Dirk (Chicago, IL);
Anderson, Jr.; Robert Anthony (Chicago, IL); Diao; Xiao Hui (Chicago, IL);
Young, Jr.; Paul Robert (Oak Park, IL); Waller; Donald Paul (Oakbrook,
IL); Garg; Sanjay (Chicago, IL); Chany, II; Calvin J. (Bolingbrook, IL)
Assignee: Rush-Presbyterian-St. Lukes Medical Center
(Chicago, IL)
Appl. No.: 252417
Filed: February 18, 1999
Abstract
A method for the reduction in the risk of transmitting a sexually
transmitted disease--especially HIV and/or HSV--during sexual activity is
provided. This method generally comprises the application of an effective
amount of an inhibitory agent, preferably as a topical formulation, to the
area or areas of sexual contact prior to engaging in sexual activity.
Inhibitory agents which are useful in the present invention include, for
example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene
sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2
SO4 -modified mandelic acids, and the like. This method can be
used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide
variety of sexual activities. In addition to anti-STD activity, these
agents may also act as vaginal contraceptives; moreover, they generally
have fewer side effects than conventional vaginal contraceptives (e.g.,
nonoxynol-9). For example, the compounds useful in this invention are
generally not toxic to natural and beneficial vaginal flora and, thus, do
not upset the local microbiological balance. The anti-STD method of the
present invention has the added advantage that it can be implemented and
controlled by either sexual party. Methods are also provided for reducing
the risk of transmission of STD-causing organisms to health care providers
and laboratory personnel (or other persons) who may come into contact with
biological samples and specimens.
SUMMARY OF THE INVENTION
This invention generally relates to a method for
preventing STDs and/or reducing the risk of transmission of such STDs
through sexual activity. This method is suitable for use by heterosexual,
homosexual, and bisexual individuals to significantly reduce the risk of
being infected by, or of transmitting, a STD through sexual contact.
Although this method can be used alone, it is generally preferred that it
be used in conjunction with other so-called "safe sex"
techniques in order to even further reduce the risk of STD transmission or
infection.
The method of this invention generally comprises the application of an
effective amount of an inhibitory agent to the area or areas of sexual
contact (e.g., genitalia) of at least one (and preferably all) of the
participants prior to engaging in sexual activity. For purposes of this
invention an "inhibitory agent" is a compound or mixture of
compounds which can inactivate at least one major STD-causing organisms
(HIV, HSV, gonococci, papilloma virus, and/or chlamydia) without
necessarily killing them. Inhibitory agents which are useful in the
present invention include, for example, phosphorylated hesperidins,
sulfonated hesperidins, polystyrene sulfonates, substituted
benzenesulfonic acid formaldehyde co-polymers, H2 SO4
-modified mandelic acids, and the like. Preferably the inhibitory agents
used in the present invention are at least partially water soluble or
water dispersable so that anti-STD formulations can more easily be
prepared.
In addition to anti-STD activity, these compounds may also act as vaginal
contraceptives and generally have fewer side effects than conventional
vaginal contraceptives (e.g., nonoxynol-9). For example, the compounds
useful in this invention are generally not toxic (or only minimally toxic)
to natural and beneficial vaginal flora and, thus, do not significantly
upset the local microbiological balance or significantly disrupt the
protective glycoprotein vaginal coating. Disruption of the natural vaginal
flora and/or removal or disruption of the protective glycoprotein vaginal
coating using conventional vaginal contraceptives can lead to irritation
of the vaginal wall and/or lesions on the vaginal wall which can make the
transmission of STD easier and/or more likely. In addition, the compounds
useful in this invention are generally not disruptive to rectal tissue and
should not, therefore, significantly contribute to the formation of
lesions or breaks in the rectal lining which could increase the risk of
STD transmission during anal intercourse.
Either party to the sexual contact can employ the method of the present
invention in order to protect him or herself and their partners. This
feature allows either party to take protective measures without relying on
the motivation or action of the other party. Of course, the highest level
of protection is obtained when both or all parties take appropriate steps
to practice the methods of this invention in conjunction with
"safe-sex" techniques.
One object of the present invention is to provide a method for reducing
the risk of transmission and infection by a sexually transmitted disease
through sexual activity between two or more parties, said method
comprising applying an effective amount of an inhibitory agent to an area
of the body to be engaged in the sexual activity of at least one of the
parties prior to the sexual activity and then engaging in the sexual
activity, wherein the inhibitory agent is selected from the group
consisting of phosphorylated hesperidins, sulfonated hesperidins,
polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde
co-polymers, and H2 SO4 -modified mandelic acids.
Another object of the present invention is to provide a method for
reducing the risk of transmission and infection by a sexually transmitted
disease through sexual activity between two or more parties, said method
comprising administering an effective amount of an inhibitory agent to the
area or areas of body of one or more of the parties in sexual contact
during the sexual activity before or after the sexual activity, wherein
the inhibitory agent is selected from the group consisting of
phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates,
substituted benzenesulfonic acid formaldehyde co-polymers, and H2
SO4 -modified mandelic acids.
Another object of the present invention is to provide a method for
reducing the risk of transmission and infection by a sexually transmitted
disease through sexual activity between two or more parties, said method
comprising applying an effective amount of an inhibitory agent to an area
or areas of the body to be engaged in the sexual activity of at least one
of the parties prior to the sexual activity, then engaging in the sexual
activity, and then applying an additional amount of the inhibitory agent
to the area or areas which was engaged in the sexual activity, wherein the
inhibitory agent is selected from the group consisting of phosphorylated
hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted
benzenesulfonic acid formaldehyde co-polymers, and H2 SO4
-modified andelic acids.
Still another object of the present invention is to provide a method for
reducing the risk of transmission and infection by a sexually transmitted
disease through sexual activity between two parties wherein the first
party is a male and the second party is a male or female and the sexual
activity involves the penis of the first party, said method comprising
applying a condom to the penis of the first party, applying an effective
amount of an inhibitory agent to an area of the body of the second party
which is to be engaged in the sexual activity or to the condom of the
first party prior to the sexual activity, and then engaging in the sexual
activity, wherein the inhibitory agent is selected from the group
consisting of phosphorylated hesperidins, sulfonated hesperidins,
polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde
co-polymers, and H2 SO4 -modified mandelic acids.
In a second embodiment, this invention also relates to methods for
reducing the risk of transmission of STDs, especially HIV/AIDS, to health
care providers or other individuals working with potentially infected
patients and/or individuals obtaining, handling, working with, or
disposing of biological samples and/or specimens from potentially infected
patients. For purposes of this invention, the phrase "health care
worker" is intended to cover doctors, dentists, nurses, dental
assistants, laboratory workers, researchers, and technical assistants,
emergency medical technicians (including police, fire, and similar
personnel), custodians, disposal personnel, and the like who are likely to
come in contact with bodily fluids found or generated in the medical
environment. Thus, still another object of this present invention is to
provide a method for reducing the risk of transmission of a sexually
transmitted disease to an uninfected individual through non-sexual contact
with the bodily fluids of a potentially sexually transmitted disease
infected person, said method comprising applying to the body or portion of
the body of the uninfected individual an effective amount of an inhibitory
agent at a time prior to likely contact with the bodily fluids or at a
time as soon as possible after actual contact with the bodily fluids,
wherein the inhibitory agent is selected from the group consisting of
phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates,
substituted benzenesulfonic acid formaldehyde co-polymers, and H2
SO4 -modified mandelic acids.
Claim 1 of 34 Claims
That which is claimed is:
1. A method for reducing the risk of transmission and infection by a
sexually transmitted disease through sexual activity between two or more
parties where the parties are not at risk of pregnancy, said method
comprising applying an effective amount of a polystyrene sulfonate to an
area of the body to be engaged in the sexual activity of at least one of
the parties prior to the sexual activity and then engaging in the sexual
activity, wherein the polystyrene sulfonate contains less than about 50
ppm dichloroethane and wherein the sexually transmitted disease is caused
by gonococci, papilloma virus, or chlamydia.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|